Enhanced Delivery Improves the Efficacy of a Tumor-specific Doxorubicin Immunoconjugate in a Human Brain Tumor Xenograft Model
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 46 (3), 704-709
- https://doi.org/10.1097/00006123-200003000-00034
Abstract
OBJECTIVE:. To evaluate dose intensification with osmotic blood-brain barrier disruption (BBBD) and the potential use of drug targeting with monoclonalKeywords
This publication has 10 references indexed in Scilit:
- The Influence of Anesthetic Choice, PaCO2, and Other Factors on Osmotic Blood-Brain Barrier Disruption in Rats with Brain Tumor XenograftsAnesthesia & Analgesia, 1999
- The next frontier of molecular medicine: Delivery of therapeuticsNature Medicine, 1998
- Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.Journal of Clinical Oncology, 1998
- Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other MeansNeurosurgery, 1998
- Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomasCancer, 1997
- Immunoconjugates and Immunotoxins for Therapy of CarcinomasPublished by Elsevier ,1995
- Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.The Journal of cell biology, 1994
- Cure of Xenografted Human Carcinomas by BR96-Doxorubicin ImmunoconjugatesScience, 1993
- Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activityCancer Immunology, Immunotherapy, 1991
- Increased Delivery of Tumor-specific Monoclonal Antibodies to Brain after Osmotic Blood-Brain Barrier Modification in Patients with Melanoma Metastatic to the Central Nervous SystemNeurosurgery, 1987